Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27699216)

Published in JCI Insight on July 07, 2016

Authors

Jesús García-Donas1, Benoit Beuselinck2, Lucía Inglada-Pérez3, Osvaldo Graña4, Patrick Schöffski2, Agnieszka Wozniak5, Oliver Bechter2, Maria Apellániz-Ruiz6, Luis Javier Leandro-García6, Emilio Esteban7, Daniel E Castellano8, Aranzazu González Del Alba9, Miguel Angel Climent10, Susana Hernando11, José Angel Arranz12, Manuel Morente13, David G Pisano4, Mercedes Robledo3, Cristina Rodriguez-Antona3

Author Affiliations

1: Oncology Unit, HM Hospitales - Centro Integral Oncológico HM Clara Campal, Madrid, Spain.; Spanish Oncology Genitourinary Group, Madrid, Spain.
2: Department of General Medical Oncology, University Hospitals Leuven, and; Laboratory for Experimental Oncology, KU Leuven, Leuven, Belgium.
3: Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.
4: Bioinformatics Unit, Structural Biology and Biocomputing Programme, Spanish National Cancer Research Centre, Madrid, Spain.
5: Laboratory for Experimental Oncology, KU Leuven, Leuven, Belgium.
6: Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain.
7: Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital Universitario Central de Asturias, Oviedo, Spain.
8: Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital Universitario 12 de Octubre, Madrid, Spain.
9: Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital Universitario Son Espases, Palma de Mallorca, Spain.
10: Spanish Oncology Genitourinary Group, Madrid, Spain.; Fundación Instituto Valenciano de Oncología, Valencia, Spain.
11: Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital Universitario Fundación Alcorcón, Madrid, Spain.
12: Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital General Universitario Gregorio Marañón, Madrid, Spain.
13: Tumour Bank Unit, Spanish National Cancer Research Centre, Madrid, Spain.

Articles citing this

microRNAs Make the Call in Cancer Personalized Medicine. Front Cell Dev Biol (2017) 0.75

miRNAs: micro-managers of anticancer combination therapies. Angiogenesis (2017) 0.75

Articles cited by this

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol (2009) 235.12

The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics (2014) 23.22

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60

miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res (2013) 13.41

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74

Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res (2008) 4.95

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev (2008) 4.25

Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat Protoc (2013) 4.00

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78

MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med (2010) 2.99

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol (2011) 2.75

MicroRNA-155 Exerts Cell-Specific Antiangiogenic but Proarteriogenic Effects During Adaptive Neovascularization. Circulation (2015) 2.73

High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat Methods (2012) 2.62

MicroRNAs as novel regulators of angiogenesis. Circ Res (2009) 2.33

Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One (2012) 1.80

Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol (2011) 1.72

TGFβ Triggers miR-143/145 Transfer From Smooth Muscle Cells to Endothelial Cells, Thereby Modulating Vessel Stabilization. Circ Res (2015) 1.62

miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med (2012) 1.49

Characterization of microRNA transcriptome in tumor, adjacent, and normal tissues of lung squamous cell carcinoma. J Thorac Cardiovasc Surg (2015) 1.46

miR-221 is required for endothelial tip cell behaviors during vascular development. Dev Cell (2012) 1.28

Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur Urol (2014) 1.21

MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res (2012) 1.21

The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med (2014) 1.16

MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One (2012) 1.07

microRNA-425-5p is upregulated in human gastric cancer and contributes to invasion and metastasis in vitro and in vivo. Exp Ther Med (2015) 1.05

Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin Chim Acta (2012) 1.05

MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases. Ann Surg Oncol (2013) 1.03

Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol (2013) 1.01

The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer (2014) 0.97

Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol (2013) 0.92

MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget (2015) 0.92

A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma. J Cancer Res Clin Oncol (2015) 0.90

Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer (2014) 0.89

MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma. Sci Rep (2015) 0.87

MiR-1 and miR-206 target different genes to have opposing roles during angiogenesis in zebrafish embryos. Nat Commun (2013) 0.86

Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One (2014) 0.85

Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. Mol Oncol (2013) 0.85

Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. Cancer Sci (2014) 0.83

miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. Mol Ther (2015) 0.82

A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. J Urol (2012) 0.82

The polymorphic terminal-loop of pre-miR-1307 binding with MBNL1 contributes to colorectal carcinogenesis via interference with Dicer1 recruitment. Carcinogenesis (2015) 0.81

Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma. FEBS Open Bio (2014) 0.81

miR-133a mediates the hypoxia-induced apoptosis by inhibiting TAGLN2 expression in cardiac myocytes. Mol Cell Biochem (2014) 0.81

Identification of potential biomarkers for clear cell renal cell carcinoma based on microRNA-mRNA pathway relationships. J Cancer Res Ther (2014) 0.79

The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer. J Ovarian Res (2015) 0.78

Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. Urol Oncol (2014) 0.78

Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma. Pharmacogenomics (2012) 0.78

Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression. PLoS One (2015) 0.77